Zolgensma Loses Orphan Benefit in Germany After 'Very High Sales'
Novartis Calls For Change In How Germany Assesses Orphan Benefit
Executive Summary
Zolgensma has exceeded the orphan sales threshold in the six months it has been on the market in Germany and the gene therapy must now undergo a full benefit assessment.
You may also be interested in...
Eyes On Pricing As Zolgensma Moves Closer To Japan Market
Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
Success For Dutch Parallel Registration and Reimbursement Pilot
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: